These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 31101580)

  • 21. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
    Motzer RJ; Tannir NM; McDermott DF; Arén Frontera O; Melichar B; Choueiri TK; Plimack ER; Barthélémy P; Porta C; George S; Powles T; Donskov F; Neiman V; Kollmannsberger CK; Salman P; Gurney H; Hawkins R; Ravaud A; Grimm MO; Bracarda S; Barrios CH; Tomita Y; Castellano D; Rini BI; Chen AC; Mekan S; McHenry MB; Wind-Rotolo M; Doan J; Sharma P; Hammers HJ; Escudier B;
    N Engl J Med; 2018 Apr; 378(14):1277-1290. PubMed ID: 29562145
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer.
    Mouri A; Kaira K; Yamaguchi O; Shiono A; Miura Y; Hashimoto K; Nishihara F; Murayama Y; Kobayashi K; Kagamu H
    Cancer Chemother Pharmacol; 2019 Oct; 84(4):873-880. PubMed ID: 31444618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab.
    Bilen MA; Dutcher GMA; Liu Y; Ravindranathan D; Kissick HT; Carthon BC; Kucuk O; Harris WB; Master VA
    Clin Genitourin Cancer; 2018 Jun; 16(3):e563-e575. PubMed ID: 29402706
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term response to immuno-oncology after discontinuation for immuno-related pneumonia in metastatic renal carcinoma: a case report.
    Stellato M; Foderaro S; Tonini G; Vincenzi B; Santini D
    Anticancer Drugs; 2022 Jan; 33(1):105-108. PubMed ID: 34232938
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial.
    George S; Motzer RJ; Hammers HJ; Redman BG; Kuzel TM; Tykodi SS; Plimack ER; Jiang J; Waxman IM; Rini BI
    JAMA Oncol; 2016 Sep; 2(9):1179-86. PubMed ID: 27243803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunotherapy in Dialysis-Dependent Cancer Patients: Our Experience in Patients With Metastatic Renal Cell Carcinoma and a Review of the Literature.
    Vitale MG; Baldessari C; Milella M; Buti S; Militello AM; Di Girolamo S; Fornarini G; Perri G; Basso U; Maruzzo M; Porta C; Cosmai L; Pipitone S; Cerma K; Cascinu S; Sabbatini R
    Clin Genitourin Cancer; 2019 Oct; 17(5):e903-e908. PubMed ID: 31375351
    [No Abstract]   [Full Text] [Related]  

  • 27. Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab.
    Ikeda T; Ishihara H; Nemoto Y; Tachibana H; Fukuda H; Yoshida K; Takagi T; Iizuka J; Hashimoto Y; Ishida H; Kondo T; Tanabe K
    Urol Oncol; 2021 Oct; 39(10):735.e9-735.e16. PubMed ID: 34172370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis.
    Josephs D; Hutson TE; Cowey CL; Pickering LM; Larkin JM; Gore ME; Van Hemelrijck M; McDermott DF; Powles T; Chowdhury P; Karapetis C; Harper PG; Choueiri TK; Chowdhury S
    BJU Int; 2011 Oct; 108(8):1279-83. PubMed ID: 21244613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety of nivolumab in metastatic renal cell carcinoma patients: A real-life experience in a Spanish urology setting.
    Amores Bermúdez J; Osman García I; Unda Urzáiz M; Jiménez Marrero P; Ledo Cepero MJ; Llarena R; Flores Martín J; Abad Vivas-Pérez JI; Rodrigo Aliaga M; Juarez Soto A
    Actas Urol Esp (Engl Ed); 2019 Sep; 43(7):364-370. PubMed ID: 31097211
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation between the magnitude of best tumor response and patient survival in nivolumab therapy for metastatic renal cell carcinoma.
    Ishihara H; Takagi T; Kondo T; Tachibana H; Fukuda H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
    Med Oncol; 2019 Mar; 36(4):35. PubMed ID: 30879157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience.
    Alhalabi O; Hasanov E; Wilson NR; Araujo J; Wang J; Campbell MT; Goswami S; Shah AY; Gao J; Msaouel P; Tannir NM
    Int J Cancer; 2021 Jul; 149(2):387-393. PubMed ID: 33739450
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elevated eosinophils proportion as predictor of immune-related adverse events after ipilimumab and nivolumab treatment of advanced and metastatic renal cell carcinoma.
    Tasaki Y; Hamamoto S; Sugiyama Y; Tomiyama N; Naiki T; Etani T; Taguchi K; Matsuyama N; Sue Y; Mimura Y; Kubota H; Noda Y; Aoki M; Moritoki Y; Nozaki S; Kurokawa S; Okada A; Kawai N; Yasui T; Kimura K
    Int J Urol; 2023 Oct; 30(10):866-874. PubMed ID: 37278575
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenomics of Metastatic Clear-Cell Renal Cell Carcinoma: Remarkable Response to Nivolumab in a Patient With a Pathogenic Germ Line BRCA1 Mutation.
    Beulque Y; Deleu AL; Punie K; De Wever L; Baldewijns M; Caruso S; Couchy G; Zucman-Rossi J; Beuselinck B
    Clin Genitourin Cancer; 2019 Oct; 17(5):e909-e912. PubMed ID: 31378579
    [No Abstract]   [Full Text] [Related]  

  • 34. Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database.
    Yekedüz E; Ertürk İ; Tural D; Karadurmuş N; Karakaya S; Hızal M; Arıkan R; Arslan Ç; Taban H; Küçükarda A; Öztaş NŞ; Sever ÖN; Uçar G; Can O; Şendur MA; Demirci U; Kılıçkap S; Çiçin İ; Öksüzoğlu B; Özgüroğlu M; Ürün Y
    Future Oncol; 2021 Dec; 17(35):4861-4869. PubMed ID: 34726480
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma.
    Tachibana H; Kondo T; Ishihara H; Fukuda H; Yoshida K; Takagi T; Izuka J; Kobayashi H; Tanabe K
    Jpn J Clin Oncol; 2021 Apr; 51(4):646-653. PubMed ID: 33212488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The prognostic impact of peripheral blood eosinophil counts in metastatic renal cell carcinoma patients treated with nivolumab.
    Yoshimura A; Nagahara A; Ishizuya Y; Yamamoto Y; Hatano K; Kawashima A; Nakai Y; Nakayama M; Nishimura K; Nonomura N; Kato T
    Clin Exp Med; 2024 May; 24(1):111. PubMed ID: 38780659
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A case of complete response to nivolumab after long-term progression-free survival with tyrosine kinase inhibitor.
    Mollica V; Di Nunno V; Corcioni B; Fiorentino M; Nobili E; Schiavina R; Golfieri R; Brunocilla E; Ardizzoni A; Massari F
    Anticancer Drugs; 2018 Oct; 29(9):911-913. PubMed ID: 29916898
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safe and effective use of nivolumab plus ipilimumab in a patient with metastatic clear-cell renal cell carcinoma with sarcomatoid dedifferentiation and end stage renal disease on hemodialysis.
    Shaw LK; Wiele AJ; Sircar K; Wood CG; Msaouel P
    Cancer Treat Res Commun; 2021; 27():100349. PubMed ID: 33725559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial.
    Pignon JC; Jegede O; Shukla SA; Braun DA; Horak CE; Wind-Rotolo M; Ishii Y; Catalano PJ; Grosha J; Flaifel A; Novak JS; Mahoney KM; Freeman GJ; Sharpe AH; Hodi FS; Motzer RJ; Choueiri TK; Wu CJ; Atkins MB; McDermott DF; Signoretti S
    Clin Cancer Res; 2019 Apr; 25(7):2174-2184. PubMed ID: 30670497
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of immunotherapy-induced immune-related adverse events.
    Kartolo A; Sattar J; Sahai V; Baetz T; Lakoff JM
    Curr Oncol; 2018 Oct; 25(5):e403-e410. PubMed ID: 30464691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.